In a sweeping move spanning nearly every corner of the country, Lannett and Bausch drug price fixing deal will cost the pharmaceutical companies $17.85 million to resolve allegations that they conspired to inflate prices of generic prescription drugs.
The proposed settlement, outlined in a motion filed Monday seeking preliminary approval, resolves claims brought by 48 states and territories accusing Lannett Company Inc., Bausch Health US LLC and Bausch Health America Inc. of coordinating to raise prices, stifle competition and restrain trade in the generic drug market.
Allegations of Artificial Price Inflation
Connecticut Attorney General William Tong, whose office is leading the broader multistate litigation, said the companies were accused of participating in long-running schemes designed to push prices upward while choking off competition.
“Lannett and Bausch both engaged in widespread conspiracies to jack up prices and block competition for generic prescription drugs,” Tong said. He added that the alleged conduct cost American families and public health care programs millions of dollars.
Under the agreement, the companies will not only pay $17.85 million but also implement internal reforms and cooperate with ongoing lawsuits. Those broader cases, spearheaded by Connecticut, target 30 corporate defendants and 25 individual executives accused of similar conduct.
The first trial in that litigation is expected to begin in late 2026 in Hartford, Connecticut.
